drugset

drugset / Trial / NCT00389441

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

NCT00389441 ↗

Phase 2 Completed 52 enrolled Pfizer

Non-randomizedSingle-groupOpen-label

Summary

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Timeline

Start: 2006-12
Primary completion: 2012-09
Completion: 2012-09

Publications

Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axitinib	Small molecule	5 mg	Oral

Indications